Nucleus Network commences Novavax' Phase 1/2 COVID-19 vaccine ...
MELBOURNE, Australia, May 26, 2020 /PRNewswire-AsiaNet/ -- Australia's largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial of NVX-CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at its Melb...
Authors: LATEST ASIANET NEWS RELEASES